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ABSTRACT
Background Impaired adrenal function is a well-described
entity in critically ill term and preterm neonates with systemic
hypotension. The standard treatment for neonatal hypotension
includes volume expanders and vasopressors. Recent
evidence supports the use of glucocorticoids for the primary
or rescue treatment of neonatal hypotension associated with
impaired adrenal function. However, inconsistency regarding
the prescribed dosing regimen to provide the best balance
between efficacy and safety in this vulnerable population
remains an area of concern.
Methods We will conduct a systematic review and
meta-analysis to evaluate low-dosing compared with
high-dosing regimens of hydrocortisone for the treatment
of hypotension in critically ill term, preterm and very
low birth weight neonates. Ovid MEDLINE, EMBASE, the
Cochrane Central Register of Controlled Trials and Web
of Science will be searched from inception to November
2021. Study screening and selection will be completed as
per the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guideline. Our primary outcomes will
be (1) an improvement in end-organ perfusion, defined
as an increase in blood pressure along with an increase
in urine output or a reduction in serum lactate and (2)
mortality prior to discharge. Our secondary outcomes will
be the development of (1) major neurosensory abnormality,
(2) bronchopulmonary dysplasia and (3) the occurrence of
adverse events.
Discussion Hydrocortisone may be beneficial in the
treatment of hypotension associated with impaired adrenal
function among critically ill neonates. However, its optimal
dosing to balance desired efficacy with the risk of adverse
events is yet to be determined. Our systematic review and
meta-analysis aims to address this evidence gap, providing
valuable knowledge for a large audience, including
guideline developers, policy-makers and clinicians.
PROSPERO registration number This protocol is
submitted for registration to the international database of
prospectively registered systematic reviews (PROSPERO,
awaiting registration number).

INTRODUCTION
The use of corticosteroids for the treatment of
hypotension associated with impaired adrenal

What is already known on this topic?
►► Critically ill and very low birth weight neonates are

at risk of developing hypotension associated with
impaired adrenal function.
►► Animal and human models support the use of glucocorticoids, such as hydrocortisone, for the treatment
of hypotension unresponsive to standard treatment.
►► Optimal dosing of hydrocortisone, to best balance
efficacy and safety, for the treatment of neonatal hypotension associated with impaired adrenal function
is unknown.

What this study hopes to add?
►► Knowledge on the efficacy of low-dosing compared

with high-dosing regimens of hydrocortisone in the
treatment of neonatal hypotension associated with
impaired adrenal function.
►► Knowledge on the safety of low-dosing compared
with high-dosing regimens of hydrocortisone in the
treatment of neonatal hypotension associated with
impaired adrenal function.
►► Knowledge on the information gaps and areas in
need of future research regarding the use of hydrocortisone in the treatment of neonatal hypotension
associated with impaired adrenal function.

function in neonates hospitalised in the intensive care unit has been described for more
than 25 years.1 Existing evidence suggests that
critically ill neonates are at risk of developing
relative adrenal insufficiency, defined as the
absence of an appropriate cortisol response
for the degree of illness.2 This condition is
thought to be associated with the downregulation of adrenergic receptors, cardiovascular
dysfunction and a deranged inflammatory
response.3
In addition to the relative adrenal insufficiency observed in critically ill term and
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preterm neonates, very low birth weight (VLBW) neonates
may also experience a suboptimal stress response and
limited cortisol production in the immediate postnatal
period.4 Possible explanations for this transient adrenal
insufficiency among VLBW neonates include their developmental immaturity and the increased demands of early
birth. Furthermore, the preterm neonate’s adrenal cortex
has a limited capacity for de novo cortisol synthesis until
30 weeks’ gestation, despite having an established hypothalamic–pituitary–adrenal axis by 20 weeks’ gestation.5 6
Thus, relatively low basal cortisol concentrations and a
reduced ability for adequate cortisol production position
the VLBW neonate for a failed stress response.7 The
possible link between inadequate cortisol production
and poor haemodynamic adaptation of VLBW infants in
the immediate postnatal period has prompted some to
question whether glucocorticoids rather than vasopressors should be the first-line pharmacotherapy for haemodynamic support in this population.3
Hydrocortisone is the glucocorticoid of choice for
the treatment of hypotension associated with impaired
adrenal function in neonates.8 Despite the lack of
convincing evidence for long-
term benefit, the short-
term efficacy of this drug has driven its continued and
widespread use.9 The significant lack of data on the pharmacokinetics and pharmacodynamics of hydrocortisone
in neonates has, however, resulted in a wide range of
dosing recommendations, with daily cumulative dosing
that may vary up to 10 times depending on the centre and
guideline. This is while available evidence has shown that
daily doses of as little as 2 mg/kg could be sufficient in
elevating the levels of steroids to stress levels and improve
end-organ perfusion.10 11 The lack of consistent dosing is
a major concern, considering the current data indicating
that exposure to hydrocortisone, especially in unnecessarily high doses and particularly in preterm neonates,
can cause serious adverse events.3 Thus, the dilemma
remains around the optimal dosing of hydrocortisone to
achieve the desired efficacy with minimal risk of short-
term and long-term adverse events.3 9
Objective
In this systematic review and meta-analysis, we aim to
determine the comparative effectiveness and safety of
low-dose versus high-dose regimens of hydrocortisone,
administered to neonates as primary or rescue therapy
for hypotension (box 1).
Hypothesis
Low-
dose hydrocortisone (initial dose of ≤1 mg/kg,
followed by ≤2 mg/kg/day or cumulative daily dose of
≤3 mg/kg on the first day of treatment) is as effective
as high-dose hydrocortisone (initial dose of >1 mg/kg,
followed by >2 mg/kg/day or cumulative daily dose of
>3 mg/kg on the first day of treatment) at improving
end-organ perfusion in critically ill neonates with hypotension.
2

Box 1

PICO framework

Population: Preterm or term neonates with postmenstrual age≤44
weeks with hypotension (defined as mean blood pressure less than
gestational age or hypotension requiring fluid or vasoactive therapy).
Intervention: Intravenous hydrocortisone initiated at any time, in
any dose and for any duration as a primary or rescue treatment for
hypotension.
Comparator: (1) Hydrocortisone compared with standard treatment,
placebo or any other vasoactive agent. (2) Low-dose (initial dose of
≤1 mg/kg, followed by ≤2 mg/kg/day) compared with high-dose (initial
dose of >1 mg/kg, followed by >2 mg/kg/day) hydrocortisone.
Outcomes: Primary—(i) Improvement in end-organ perfusion
defined as an increase in mean, diastolic or systolic blood pressure
within 1 hour of the start of treatment with one of the additional
following criteria: an increase in urine output or a reduction in serum
lactate within 12 hours of treatment initiation, as defined by the
authors in the primary studies and (2) mortality prior to discharge.
Our secondary outcomes are (1) development of bronchopulmonary
dysplasia, (2) development of major neurosensory disability defined
as moderate to severe motor or cognitive impairment or severe visual
or hearing impairment as identified in the primary study and (3)
occurrence of adverse events defined as hypertension, hyperglycemia,
gastrointestinal events (occurrence of gastrointestinal perforation,
necrotising enterocolitis or gastrointestinal bleed), or hospital-acquired
infection within 2 weeks of hydrocortisone administration
Study designs: Randomised and non-randomised controlled trials,
cohort studies.

MATERIALS AND METHODS
Protocol registration
The Preferred Reporting Items for Systematic Reviews
and Meta-
Analyses Protocol (PRISMA-
P)12 statement
was used to guide the reporting of this protocol. The
Meta-analyses Of Observational Studies in Epidemiology
Checklist12 and the PRISMA statement13 will be used to
guide the reporting of the final review and meta-analysis.
Search strategy and data sources
A comprehensive search strategy will be developed
in consultation with a professional librarian for the
following electronic databases: Ovid EMBASE (1974 to
November 2021), Ovid MEDLINE (1964 to November
2021), Web of Science (1900 to November 2021) and the
Cochrane Central Register of Controlled Trials (online
supplemental figure 1). The search strategy will first
be developed in MEDLINE (Ovid interface) and will
contain database-specific subject headings and text word
terms for concepts. The search strategy will be translated
as appropriate for the other databases. A peer review of
our search strategy using the Peer Review for Electronic
Search Strategies guideline14 will be completed by a
professional librarian (online supplemental appendix).
We will also search the bibliographies of included studies
and relevant reviews for additional references and seek
out relevant studies that are not commercially published,
such as ongoing or unpublished clinical trials (WHO
International Clinical Trials Registry Platform, European Clinical Trials Database and C
linicaltrials.
gov),
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conference proceedings and abstracts (Conference
Proceeding Citation Index, Web of Science), dissertations
and thesis (OpenGrey and ProQuest) and book chapters.
We will also contact study authors to clarify information
when necessary. Animal studies and duplicate studies will
be excluded. We will not apply any language or study
design limitations.
Eligibility criteria
Randomised and non-randomised controlled trials and
prospective and retrospective cohort studies describing
the use of intravenous hydrocortisone as primary or
rescue treatment for hypotension in preterm and term
neonates with post menstrual age of ≤44 weeks that
describe mortality prior to discharge or improvement in
end-organ perfusion as defined by our primary outcomes
will be eligible for inclusion, irrespective of the dose and
frequency of administration and duration of treatment
(box 1). We will include both studies comparing low-dose
versus high-dose hydrocortisone and studies comparing
low dose or high dose with placebo, or no control or any
other vasoactive agent.

Table 1 Data extraction form for studies included in the
review and meta-analysis
General information
 Data form completed (dd/mm/yyyy)

 

 Name/ID of data extractor

 

 Study ID
 Author last name_study year

 

 Study citation

 

 Year of study conduct

 

 Country of study conduct

 

 Funding source

 

 Conflict of interest

 

Characteristics of included studies
Methods
 Aim of study

 

 Study design

 

 Method of randomisation

 

 Start date

 

 End date

 

Study selection and data extraction
Covidence15 will be used as the primary screening and
data extraction tool. Following deduplication, two independent reviewers (NA-R and KS) will screen the resulting
articles at the title and abstract level for eligibility.
Eligible articles will then be independently reviewed at
the full-text level by the same two reviewers. A PRISMA
flow diagram will be created to illustrate the study selection process. Data will then be extracted by the same
reviewers in duplicate related to the population, intervention, control and outcome for each study (table 1).
Any identified discrepancies throughout the study selection and data extraction process will be resolved by
discussion between three reviewers (NA-R, KS and SS-Z).
The authors of the included studies will be contacted in
the case of unclear or missing information.

Participant characteristics

Assessment of risk of bias and certainty of evidence
Two reviewers (NA-R and KS) will independently evaluate
the methodological quality of the included studies using
standardised risk of bias assessment tools, including V.2 of
the Cochrane risk-of-bias tool (RoB V.2) for randomised
trials,16 risk of bias in non-randomised studies of interventions17 and the Newcastle-Ottawa Quality Assessment
Scale for cohort studies.18 We determined a priori that
Newcastle-Ottawa Quality Assessment Scale scores of 0–3,
4–6 and 7–9 will be considered high, moderate and low
risk of bias, respectively.19 Using the Grading of Recommendations Assessment, Development, and Evaluation
approach,20 two reviewers (NA-
R and KS) will independently judge the certainty of the evidence. Any disagreement will be solved through discussion with a third
reviewer (SS-Z).

Hydrocortisone details

Outcomes and variable
Our primary outcomes are (1) improvement in end-organ
perfusion, defined as an increase in mean, diastolic or
Sushko K, et al. BMJ Paediatrics Open 2021;5:e001200. doi:10.1136/bmjpo-2021-001200

 Population description

 

 Setting

 

 Inclusion criteria

 

 Exclusion criteria

 

 Number of participants

 

 Baseline imbalances*

 

 Birth weight (grams)

 

 Gestational age (weeks)

 

 Postnatal age (hours, days or weeks)  
 Underlying condition/cause of
hypotension

 

 Comorbidities

 

 Concurrent medications

 

Intervention/exposure characteristics
 Timing of administration
 Primary or rescue therapy or other

 

 Dosing details
 Initial dose (mg/kg)
 Maintenance dose (mg/kg/day)
 Treatment interval (hours)
 Treatment length (hours)
 Cumulative dose (mg/kg)

 

Control/comparator details
 Pharmacotherapy
 Dopamine
 Dobutamine
 Epinephrine
 Norepinephrine
 Milrinone
 Vasopressin
 Placebo
 Other

 

Outcomes details†

Continued
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Table 1 Continued

Table 2 Primary and secondary outcome variables*

Primary outcomes
 

Improvement
Yes or No

If Yes,
Timing‡

Primary outcomes

Primary outcome variables

 SBP

 

 

 DBP

 

 

Improvement in end-organ
perfusion

 MBP

 

 

 Urine output

 

 

 Inotropic support

 

 

►► SBP
►► DBP
►► MBP
►► Urine output
►► Inotropic support
►► Serum lactate

 Serum lactate

 

 

Mortality

►► Death before discharge

 Mortality

Death in the ICU
Yes or No

 

Secondary outcomes

Secondary outcome variables†

Major neurosensory
disability

►► Moderate to severe motor

Secondary outcomes§

impairment

Major neurosensory disability
 Moderate to severe motor
impairment

 

 Moderate to severe cognitive
impairment

 

 Cerebral palsy

 

 Visual impairment

 

 Hearing impairment

 

 BPD

 

►► Cerebral palsy
►► Visual impairment
►► Hearing impairment

BPD
Occurrence of adverse
events

 Gastrointestinal events

 

 Hyperglycemia

 

Adverse events
►► Hyperglycemia
►► Gastrointestinal events
►► Hospital-acquired infection
►► Hypertension

*The primary and secondary outcome variables are defined as
per the primary studies.
†For all secondary outcome variables, the number or % in
exposed versus unexposed groups; attributed to hydrocortisone
will be applied for the analysis.
BPD, bronchopulmonary dysplasia; DBP, diastolic blood
pressure; MBP, mean blood pressure; SBP, systolic blood
pressure.

Occurrence of adverse events

Hypertension
Hospital acquired infection
*Statistically significant (p<0.05) differences in baseline characteristics
between intervention and control or exposed and unexposed
participant groups, as reported by the study authors.
†The primary and secondary outcome variables are defined as per the
primary studies.
‡Within first 12 hours of treatment initiation.
§For all secondary outcome variables, the number or % in exposed
vs unexposed groups; attributed to hydrocortisone will be applied for
the analysis.
BPD, bronchopulmonary dysplasia; DBP, diastolic blood pressure;
ICU, intensive care unit; MBP, mean blood pressure; SBP, systolic
blood pressure.

systolic blood pressure within 12 hours of the start of treatment, with one of the additional following criteria: an
increase in urine output or a reduction in serum lactate
within 12 hours of treatment initiation, as defined by the
authors in the primary studies and (2) mortality prior to
discharge.
Our secondary outcomes are (1) development of bronchopulmonary dysplasia, (2) major neurosensory disability,
defined as moderate to severe motor or cognitive impairment, cerebral palsy, or severe visual or hearing impairment as defined in the primary study and (3) occurrence
of adverse events defined as hypertension, hyperglycemia,
gastrointestinal events (occurrence of gastrointestinal perforation, necrotising enterocolitis or gastrointestinal bleed),
or hospital-acquired infections within 2 weeks of hydrocortisone administration (table 2).
4

impairment

►► Moderate to severe cognitive

Data synthesis and statistical analysis
A meta-analyses will be performed for randomised and
non-randomised studies, separately using the following
comparisons:
1. Comparison 1: We will perform a meta-
analysis of
studies comparing low-dose (initial dose of ≤1 mg/kg,
followed by ≤2 mg/kg/day or cumulative daily dose of
≤3 mg/kg on the first day of treatment) with high-dose
(initial dose of >1 mg/kg, followed by >2 mg/kg/day
or cumulative daily dose of >3 mg/kg on the first day
of treatment) hydrocortisone. In this meta-
analysis,
the studies will be grouped based on the indication of
treatment, such as, transient adrenal insufficiency in
preterm infants and hypotension in critically ill term
neonates.
2. Comparison 2: We will perform a meta-analysis of studies comparing hydrocortisone (any dose, low or high)
with placebo or no medication or any other vasoactive
agent. In this meta-analysis, the studies will be grouped
based on the dose of hydrocortisone (low dose or high
dose) to test for subgroup differences between low-
dosing and high-dosing regimens.
For dichotomous outcomes, we will obtain the raw
data from each study to calculate relative risk (RR) and
95%CI. We will use a random effects model to perform
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the meta-analyses using Review Manager V.5.4 (Cochrane
Collaboration, Nordic Cochrane Center, Copenhagen,
Denmark) to yield pooled RR and its 95% CI for each
outcome. As risk data for observational studies are
usually provided as odds ratios (OR), we plan to convert
the ORs to RRs prior to meta-analysis. Individual studies
that provide multiple ORs or RRs stratified by gestational
age will be pooled using a fixed-effect model method
to obtain a combined risk for the whole population
included in the individual study. Publication bias will be
visually assessed using a funnel plot21 and Egger’s regression test22 if more than 10 studies are included for any
individual meta-analysis.
Assessment of heterogeneity
The pooled forest plots will be visually evaluated to assess
for heterogeneity. Furthermore, we will determine the
statistical heterogeneity using the p for χ2 and I2 values
(derived from the χ2 Q-statistic) in the meta-analysis.23
Statistical heterogeneity will be considered significant if
the p value for χ2 is <0.10. On identifying significant statistical heterogeneity, the data will be checked for mistakes
and inconsistencies during the data extraction and data
entry processes. We will perform subgroup analysis based
on gestational age (<28 weeks and >28 weeks), if data are
available, to explore the heterogeneity.
Patient and public involvement
Patients or the public were not involved in the design,
or conduct, or reporting, or dissemination plans of our
research.

DISCUSSION
This review will include a comparative analysis of
commonly prescribed dosing regimens of hydrocortisone
in neonates. It will also investigate whether the efficacy
and safety profile of high-dosing versus low-dosing regimens justifies the use of one universal recommendation.
Evidence from the review will assist in the development
of guidelines and clinical recommendations for critically
ill neonates with hypotension as well as identify knowledge gaps and areas in need of further research related
to glucocorticoids in the treatment of neonatal hypotension. The results of this review will be of interest to a
broad audience, including policy-makers and guideline
developers, neonatologists and paediatric intensivists.
The strengths of our study include the use of explicit and
reproducible methods to produce a rigorous and high-
quality evidence synthesis.

DEFINITIONS
We will define two dosing regimens of high-dose (initial
dose of >1 mg/kg, followed by >2 mg/kg/day or cumulative daily dose of >3 mg/kg on the first day of treatment) and low-dose (initial dose of ≤1 mg/kg, followed
by ≤2 mg/kg/day or cumulative daily dose of ≤3 mg/kg

on the first day of treatment) hydrocortisone therapy3 24
to assess their comparative effectiveness and safety.
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